Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
Date:10/23/2007

CALGARY, Oct. 24 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that a poster presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN(R)/radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The conference runs from October 22-26, 2007.

"We are very encouraged with the results of this trial to date," said Dr. Brad Thompson, President and CEO of Oncolytics. "The data is supportive of our ongoing Phase II REOLYSIN(R)/radiation cotherapy trial in the U.K."

The interim results of the Ia/Ib trial demonstrate that intratumoural treatment with REOLYSIN(R) and radiation is well tolerated and results in both local and remote anti-tumour activity in patients with a variety of advanced cancers. Oncolytics continues to enroll patients in the Ib portion of this trial, and is also actively enrolling patients in a Phase II trial examining this treatment combination.

The presentation, entitled "A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN(R)) in combination with radiation in patients with advanced malignancies" will be delivered by Dr. Dean Harris of The Institute of Cancer Research, London.

These interim results were also presented in early October at the National Cancer Research Institute (NCRI) Cancer Conference in Birmingham, U.K.

The poster presentation will be posted on the Oncolytics website today at http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... BioSciences, Inc. (NASDAQ: SGMO ) announced today that ... update on the progress of Sangamo,s ZFP Therapeutic ® ... at 1:30pm ET on Monday, June 1, 2015, at the ... in New York, NY . ... via a link on the Sangamo BioSciences website in the ...
(Date:5/26/2015)... , May 26, 2015  Alere Inc. (NYSE: ALR ... its failure to timely file its Quarterly Report on Form ... "Form 10-Q"), it has received a notice from the New ... in compliance with the NYSE,s continued listing requirements under the ... Listed Company Manual. The reason for the ...
(Date:5/26/2015)... Miami, FL (PRWEB) May 26, 2015 ... training, Inc. have announced plans for the company’s first ... 9, 2015, followed by a full day, hands-on stem ... hosted by J. Victor Garcia Gimenez, M.D., President of ... to the medical community’s increasing interest in regenerative medicine ...
(Date:5/26/2015)...   PDI , a leader in infection ... Healthcare in Dearborn, Mich. ... Delivering the Difference , a ... building collaborative relationships between infection prevention (IP) and ... Oakwood Healthcare,s infection preventionist, Priscila ...
Breaking Biology Technology:Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3
... revolutionary surgical instrument system that is smaller in diameter than a ... implantation of the VerteLoc™ Minimally Invasive Spine Stabilization System and will ... Arizona starting on March 12, 2009. , ... Winston-Salem, ...
... In ClearTrial v2.7, the newest version of ... Portfolio Planning capability which enables clinical development ... into portfolio-level forecasts in minutes. The ... monthly resource demand, and timelines across a ...
... Enobia Pharma, an emerging Canadian biotech company ... disorders, today announced completion of target enrollment in ... a severe form of hypophosphatasia. Enobia is ... the treatment of this rare and often crippling ...
Cached Biology Technology:VGI Announces the Launch of DISMISS Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 3ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 4Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 3
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... June 15 Robert H. Wurtz, PhD, a pioneer and ... the 2010 Neuroscience Prize of The Peter and Patricia Gruber ... and controls eye movements laid the groundwork for subsequent research ... scientists to a deeper understanding of how the brain is ...
... new study shows that humans and tiny aquatic animals known ... to sex. Barely visible without a microscope, rotifers eat ... But the females of certain rotifer species can do something ... themselves, or they can initiate a process that allows sexual ...
... part of the 20th century have prevented massive amounts ... equivalent of 590 billion metric tons of carbon dioxide ... Stanford Earth scientists. The yield improvements reduced the ... typically involves burning of trees and other plants, which ...
Cached Biology News:Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 2Neuroscientist Robert H. Wurtz receives the $500,000 Gruber neuroscience prize 3New study documents use of hormone progesterone in simple microscopic aquatic animals 2New study documents use of hormone progesterone in simple microscopic aquatic animals 3New study documents use of hormone progesterone in simple microscopic aquatic animals 4High-yield agriculture slows pace of global warming, say Stanford researchers 2High-yield agriculture slows pace of global warming, say Stanford researchers 3High-yield agriculture slows pace of global warming, say Stanford researchers 4
... (phospho S207) ( Abpromise for ... Antigen: Synthetic phosphopeptide derived from ... of Serine 207 (V-D-S P -V-A). ... 5608 Swiss ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: